|This Slide: #57 of 100|
Slide #57. Pfizer — Polocard
Pfizer Inc. (NYSE:PFE) today announced that a wholly-owned Polish subsidiary of Pfizer has acquired the rights to Polocard, a low-dose aspirin (acidum acetylsalicylicum), and the leading over-the-counter (OTC) brand for heart attack prevention in Poland, from ZF Polpharma SA.
Pfizer is a research-based, global biopharmaceutical company. Co. is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. Co. collaborates with healthcare providers, governments and local communities to support and expand access to healthcare around the world. Co. provides vaccines across various ages (infants, adolescents and adults) in pneumococcal disease, meningococcal disease, tick-borne encephalitis and novel coronavirus disease of 2019 (COVID-19). Key products include: Comirnaty/BNT162b2, the Prevnar family, Nimenrix, FSME/IMMUN-TicoVac and Trumenba.
Pfizer SEC Filing Email Alerts Service
Open the PFE Page at The Online Investor »
Free PFE Email Alerts:
Get SEC Filing Alerts
Get Dividend Alerts
Buy (3.27 out of 4)